Anika Therapeutics, Inc. (NASDAQ:ANIK)
The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Haugurafpeningum
(98.39)
Submitted: 11/8/2011 2:34:55 AM :
Start Price:
$7.90
ANIK Score:
+28.69
Technical Monthly
Recs
acts20
(85.36)
Submitted: 9/30/2011 10:11:30 AM :
Start Price:
$5.41
ANIK Score:
+79.75
Ceo sucks. But at low. Buy out prospect. New products
Recs
siri22
(< 20)
Submitted: 8/31/2011 5:53:55 PM :
Start Price:
$6.00
ANIK Score:
+67.30
Ceo sucks.....but low end...good products
Recs
tunstavurn
(< 20)
Submitted: 3/2/2011 5:24:57 PM :
Start Price:
$9.19
ANIK Score:
-14.19
Pending lawsuit with genzyme.
declining margins
Increased competition
Recs
Biotechfreak
(< 20)
Submitted: 2/24/2011 12:09:17 AM :
Start Price:
$8.52
ANIK Score:
+22.11
Anika Therapeutics has tremendous upside Potential in the near term .
Anika awaiting 4 FDA approvals in the 1H 2011 .The Biotech Company is profitable and cash flow positive .
Anika is definitely one of the best Pick in the Biotech sector .
Recs
depletemycapital
(< 20)
Submitted: 2/14/2011 6:34:12 PM :
Start Price:
$8.25
ANIK Score:
-27.84
what a horror show. they cant get anything right! all the products being wasted. morons @ the helm! how do you not know for sure that the FDA would not allow you to manufacture opthalmic products without all equipment in a new facility?
What they gave a thumbs up & then changed their mind?! so much loss of capital with this company.
they wasted elevess or hydrelle or whatever they call it now. couldn't reach a marketing agreement with Galderma! Then coapt systems, which went bankrupt. for crying out loud coapt systems was even smaller than anika!
Then monovisc. They were gonna work on the salesforce starting last qtr. what are the odds they even had resume's! Should have never invested in this comapny! never! never!
Oh! the horror! the horror! I wonder how they'll respond to this. i hope the 4th qtr will have had some earnings good news. BUT I RATHER DOUBT IT!!!
Please don't believe this stock has any value. for eternity. somebody will buy this for 5 bucks a share! how much cash these guys made on stockoptions, is unbelievable! i need patience like ATVI, but i've gone thru this for 4 years now.what a loss. but i've got to stick it thru for another 2 years of excuses!
Recs
gsabc
(74.68)
Submitted: 6/25/2010 9:09:25 AM :
Start Price:
$6.16
ANIK Score:
+47.86
Small company with very low price-to-book at the moment, but good products , solid revenue stream and great potential growth.
Recs
MAD66
(61.54)
Submitted: 6/4/2008 12:57:47 PM :
Start Price:
$8.81
ANIK Score:
+20.03
Good entry point.
Recs
ZoomAddict111
(< 20)
Submitted: 5/8/2008 1:03:13 AM :
Start Price:
$10.53
ANIK Score:
+1.27
Strong pipeline/partnerships/mgt. Beaten down by econ fears. Hold until it outperforms the market by thirty percent or so. PE when added was 20.2
Recs
capsterok
(79.80)
Submitted: 4/21/2008 3:42:40 PM :
Start Price:
$9.29
ANIK Score:
+10.04
Testing out a portfolio of smallish-cap 5-star stocks found using the CAPS screener. All picks have at least 50 allstars backing them, which should be enough to minimize star rating fluctuations. It's been less than a week, but so far so good!
Recs
LetterA
(88.27)
Submitted: 4/6/2008 2:50:07 AM :
Start Price:
$9.82
ANIK Score:
+7.21
Testing a portfolio of companies that start with the letter "A".
Recs
Killa2dahead
(45.23)
Submitted: 4/3/2008 3:32:19 AM :
Start Price:
$9.29
ANIK Score:
+11.97
sounds cool
Recs
geostathis
(57.15)
Submitted: 2/8/2008 4:36:22 PM :
Start Price:
$11.31
ANIK Score:
-11.22
Extremely low Enterprise value. Growing and accelerating earnings. Unfairly punished
Recs
lepersinmyhead
(55.53)
Submitted: 2/5/2008 10:01:59 PM :
Start Price:
$11.09
ANIK Score:
-8.19
Great
value at this price.
Recs
zzlangerhans
(99.26)
Submitted: 1/9/2008 8:17:38 PM :
Start Price:
$13.06
ANIK Score:
-18.86
Anika has a very low market cap given the number and variety of products it is already marketing. Quarterly revenues have substantial potential for growth given planned launch of Monovisc in Europe this quarter and possible new marketing deal for Elevess this year. They have also made progress in their pipeline, recently initiating a pivotal US trial for Monovisc. All the recent news has been good, but the stock price has been dipping. There is almost no short interest and a reasonable financial bottom line, so it's hard to see any justification for the recent decline. 13 may not be the bottom, but it seems like a pretty nice entry point.
Recs
bridgeboy0
(99.96)
Submitted: 11/9/2007 1:34:19 PM :
Start Price:
$13.60
ANIK Score:
-18.17
From Motley Fool hard to meet screen.
Recs
electrius
(< 20)
Submitted: 10/6/2007 4:42:21 PM :
Start Price:
$20.59
ANIK Score:
-38.97
Elevess and host of future related products, marketed by Galderma will provide growth for multiple years. Already profitable and no debt.
Recs
suave1007
(< 20)
Submitted: 8/14/2007 6:54:48 PM :
Start Price:
$16.75
ANIK Score:
-35.64
Relatively unknown:"BEST Vanity and Youth Play" thru FDA approved hyloranian acid for orthoritis of knee and removal of aging facial lines. Tripling pdtn facility for future growth. Place limit orders: thin stock.
Recs
luke44
(70.40)
Submitted: 7/18/2007 7:36:16 PM :
Start Price:
$16.50
ANIK Score:
-26.71
he Company develops, manufactures and commercializes therapeutic products for tissue protection and healing
Recs
SteadySaber
(76.00)
Submitted: 6/8/2007 5:04:37 PM :
Start Price:
$15.45
ANIK Score:
-25.31
New products second half. P/E looks high. Any room to make some money?
This year's earnings trade at a 29 p/e for .51 est. With a ttm p/e of 36. So lets say they hit the numbers and get .51. That should imply an $18 stock based on the ttm p/e of 36. It woud seem 36 is pretty high and I would bet the TTM goes down more than up. So 20% upside doesn't give much room for comfort if we look at backwards p/e.
New things are coming so maybe forward p/e is the better metric. Say they hit .51 and the following years est. is .79 according to the analysts right now. Based on the current forward p/e of 29 (off of the .51 est) gets you a $22 stock on .79 after they hit the .51 numbers. So there you have it - this stock should trade between 18 and 22 by the end of the fiscal year. More likely 22. That's assuming the new products will really generate the growth that this p/e imply.
For the risk assumed about the new products, investors can expect a tiddy 46% profit if it paysoff.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 32 : 1 2 Next »